1887

n Cardiovascular Journal of South Africa - CHARM shows improvement in NYHA functional class with candesartan : drug trends in cardiology

USD

 

Abstract

Extracted from text ... 96 Data presented at the 2004 meeting of the American College of Cardiology held last month adds weight to the evidence of the value of candesartan cilexetil in the treatment of chronic heart failure in the CHARM study (Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity).1, 2 Importantly, an analysis3 found that New York Heart Association (NYHA) functional class improved in a broad spectrum of CHF patients treated with candesartan. Of all CHARM patients, 35.4% taking candesartan improved in NYHA functional class, 55.6% remained unchanged and 9% worsened. This compared with 32.5%, 57.5% and 10.3%, respectively, in ..

Loading

Article metrics loading...

/content/cardio/15/2/EJC23887
2004-03-01
2016-12-04
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error